In Brief: Thompson Medical
This article was originally published in The Tan Sheet
Executive Summary
Thompson Medical: Submits results from a new double-blind placebo-controlled clinical trial in support of its petition to FDA seeking Category I status for trolamine salicylate, the active ingredient in Aspercreme ("The Tan Sheet" Jan. 24, 1994, p. 16). The June 12 submission supports the effectiveness of the ingredient as a topical analgesic for the relief of pain and stiffness associated with arthritis, Thompson Med says, and further confirms the results of the two clinical trials that have already been provided to FDA ("The Tan Sheet" May 9, 1994, In Brief)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning